Using PhytoSERM to Improve Brain Health in Menopausal Women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 clinical trial aims to evaluate the safety and effectiveness of the phytoestrogenic supplement PhytoSERM on brain metabolism and cognition in peri- and postmenopausal women. Participants will be randomly assigned to receive either PhytoSERM or a placebo for 24 weeks, with assessments including cognitive tests and brain imaging using FDG-PET to measure glucose metabolism. The study will also monitor safety and tolerability throughout the trial period. A subset of participants will undergo a pharmacokinetic study to analyze the supplement's absorption and effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Peri- or postmenopausal women with the latter defined as last menstrual period (LMP) completed ≥ 60 days and ≤ 4 years, per the Stages of Reproductive Aging Workshop (STRAW) criteria.
2. Age 45-60 years.
3. Presence of hot flashes ≥ 7 per day.
4. In good general health as evidenced by medical history.
5. Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be not clinically significant by the investigator.
6. No medical contraindications to study participation.
7. Stable medications for 4 weeks prior to the baseline visits.
8. Provision of signed and dated informed consent form.
9. Stated willingness to comply with all study procedures and availability for the duration of the study.
10. Ability to take oral medication and be willing to adhere to the PhytoSERM regimen.
11. For females of reproductive potential: Negative pregnancy test and use of highly effective contraception by male partner for at least 1 month prior to screening and agreement to use such a method during study participation.
12. Fluent in English or Spanish.

Exclusion Criteria:

1. Known allergies to isoflavones or soy-based products.
2. Evidence of cognitive impairment on the Mini-Mental State Examination (total score \< 27).
3. Pregnancy
4. Use of estrogen or progestin compounds within 8 weeks of baseline.
5. Use of investigational agent within 12 weeks of baseline.
6. Concurrent neurologic, systemic, or psychiatric disease that would influence cognition or ability to provide informed consent and to participate.
7. Known or suspected estrogen-dependent neoplasia, active neoplastic disease, history of breast cancer, or at risk of developing breast cancer, endometrial hyperplasia.
8. History of epilepsy, focal brain lesion, head injury with loss of consciousness or Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse.
9. Thrombophlebitis, thrombosis, thromboembolic disorders, myocardial infarction, ischemic heart disease, cerebrovascular accident, stroke, transient ischemic attack (TIA).
10. Current use of tobacco or a history of alcohol abuse.
11. Use of drugs, herbs, or dietary supplements to treat menopausal or cognitive symptoms less than 8 weeks prior to baseline.
12. Evidence of any significant clinical disorder or laboratory finding.
13. Known allergy to soy-derived products/ proteins or branded over the counter products; hypersensitivity to estrogens or progestins.
14. Visual and auditory acuity inadequate for neuropsychological testing
15. Inability to undergo MRI scans
16. Inability to undergo PET scans

Where it's running

• The Alzheimer's Prevention Program / Weill Cornell Medicine
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Roberta D Brinton, PhD — University of Arizona
• Study coordinator: Claudia M Lopez, BS
• Email: claudiml@arizona.edu
• Phone: 5206266276

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hop extract vs soy isoflavone for menopausal symptoms

  This study tests whether a full-spectrum hop extract helps reduce menopausal mood symptoms better than soy isoflavones in peri- and postmenopausal women.

  Recruiting Menoclinica by Palacios · Madrid, Madrid · NCT07904390

• Resveratrol and Estrogen Receptors in Postmenopausal Women with CAD

  This study tests whether taking resveratrol is safe and can change estrogen-related markers in postmenopausal women with coronary artery disease.

  Recruiting InCor Heart Institute · São Paulo, São Paulo · NCT07865377

• Ashoka Bark and Shatavari for Menopause

  This 12-week study tests whether a daily Ashoka Bark and Shatavari supplement helps reduce menopausal symptoms in postmenopausal women compared with a placebo.

  Recruiting Vidya USA Corporation · New Port Richey, Florida · NCT07861295

• Lifestyle changes to ease menopausal symptoms, sleep problems, and anxiety

  Researchers are testing whether a structured lifestyle education program helps perimenopausal and postmenopausal women see fewer menopausal symptoms, better sleep, and less anxiety compared to usual care.

  Recruiting Konya Beyhekim Training and Research Hospital · Konya, Konya · NCT07860645

• Pain and period life: does menstrual cycle or menopause change pain during root canals?

  This study will see if pain during a root canal varies with menstrual cycle phase or menopausal status in adult patients.

  Recruiting Nigde Omer Halisdemir University · Niğde · NCT07850167

• Sex hormones, menopause, and exercise in aging women

  This study tests how hormonal status and resistance training affect age-related muscle and nerve function in postmenopausal women.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT07848438

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.